The results showed that inhibition of S100A8 significantly increased the sensitivity of glioma cells to TMZ treatment, which further validated the important role of S100A8 in GBM for therapeutic resistance (Supplementary Fig. S8D). This evidence concerns the gene S100A8 and central nervous system cancer.